Synthon is proud to announce the completion of two successful bioequivalence (BE) studies for Bempedoic acid, a product we are developing for our valued partners.

 In two pivotal BE studies for the US, bioequivalence has been shown between Synthon’s Bempedoic acid 180 mg film-coated tablets and Nexletol 180 mg tablets. The two BE studies were conducted in healthy volunteers in fasting and in fed conditions.  

Our successful studies are a significant milestone in our mission to create a high-value portfolio of complex generic products and to make a meaningful difference in the lives of patients.

     Share this page